Structure-based optimization of free fatty acid receptor 1 agonists bearing thiazole scaffold

被引:16
作者
Li, Zheng [1 ]
Xu, Xue [2 ]
Hou, Jie [1 ]
Wang, Shaohong [1 ]
Jiang, Hongwei [1 ]
Zhang, Luyong [1 ,3 ,4 ]
机构
[1] Guangdong Pharmaceut Univ, Sch Pharm, Guangzhou 510006, Guangdong, Peoples R China
[2] Guangzhou Gen Pharmaceut Res Inst Co Ltd, Guangzhou 510240, Guangdong, Peoples R China
[3] Guangdong Pharmaceut Univ, Guangzhou Key Lab Construct & Applicat New Drug S, Guangzhou 510006, Guangdong, Peoples R China
[4] China Pharmaceut Univ, Jiangsu Key Lab Drug Screening, Nanjing 210009, Jiangsu, Peoples R China
基金
中国国家自然科学基金;
关键词
Diabetes; FFA1; Hyperglycemia; Insulin secretion; Ligand efficiency; DRUG DISCOVERY; POTENT; GPR40; DESIGN; DERIVATIVES; IDENTIFICATION; EFFICACY; GLUCOSE; SAFETY;
D O I
10.1016/j.bioorg.2018.01.039
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The free fatty acid receptor 1 (FFA1) plays an important role in amplifying insulin secretion in a glucose dependent manner. We have previously reported a series of FFA1 agonists with thiazole scaffold exemplified by compound 1, and identified a small hydrophobic subpocket partially occupied by the methyl group of compound 1. Herein, we describe further structure optimization to better fit the small hydrophobic subpocket by replacing the small methyl group with other hydrophobic substituents. All of these efforts resulted in the identification of compound 6, a potent FFA1 agonist (EC50 = 39.7 nM) with desired ligand efficiency (0.24) and ligand lipophilicity efficiency (4.7). Moreover, lead compound 6 exhibited a greater potential for decreasing the hyperglycemia levels than compound 1 during an oral glucose tolerance test. In summary, compound 6 is a promising FFA1 agonist for further investigation, and the structure-based study promoted our understanding for the binding pocket of FFA1. (C) 2018 Elsevier Inc. All rights reserved.
引用
收藏
页码:429 / 435
页数:7
相关论文
共 46 条
  • [1] A simple reduction of methyl aromatic esters to alcohols using sodium borohydride-methanol system
    Boechat, N
    da Costa, JCS
    Mendonça, JD
    de Oliveira, PSM
    de Souza, MVN
    [J]. TETRAHEDRON LETTERS, 2004, 45 (31) : 6021 - 6022
  • [2] The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids
    Briscoe, CP
    Tadayyon, M
    Andrews, JL
    Benson, WG
    Chambers, JK
    Eilert, MM
    Ellis, C
    Elshourbagy, NA
    Goetz, AS
    Minnick, DT
    Murdock, PR
    Sauls, HR
    Shabon, U
    Spinage, LD
    Strum, JC
    Szekeres, PG
    Tan, KB
    Way, JM
    Ignar, DM
    Wilson, S
    Muir, AI
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (13) : 11303 - 11311
  • [3] Discovery of AM-1638: A Potent and Orally Bioavailable GPR40/FFA1 Full Agonist
    Brown, Sean P.
    Dransfield, Paul J.
    Vimolratana, Marc
    Jiao, XianYun
    Zhu, Liusheng
    Pattaropong, Vatee
    Sun, Ying
    Liu, Jinqian
    Luo, Jian
    Zhang, Jane
    Wong, Simon
    Zhuang, Run
    Guo, Qi
    Li, Frank
    Medina, Julio C.
    Swaminath, Gayathri
    Lin, Daniel C. -H.
    Houze, Jonathan B.
    [J]. ACS MEDICINAL CHEMISTRY LETTERS, 2012, 3 (09): : 726 - 730
  • [4] Identification of a Potent and Selective Free Fatty Acid Receptor 1 (FFA1/GPR40) Agonist with Favorable Physicochemical and in Vitro ADME Properties
    Christiansen, Elisabeth
    Urban, Christian
    Grundmann, Manuel
    Due-Hansen, Maria E.
    Hagesaether, Ellen
    Schmidt, Johannes
    Pardo, Leonardo
    Ullrich, Susanne
    Kostenis, Evi
    Kassack, Matthias
    Ulven, Trond
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2011, 54 (19) : 6691 - 6703
  • [5] National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants
    Danaei, Goodarz
    Finucane, Mariel M.
    Lu, Yuan
    Singh, Gitanjali M.
    Cowan, Melanie J.
    Paciorek, Christopher J.
    Lin, John K.
    Farzadfar, Farshad
    Khang, Young-Ho
    Stevens, Gretchen A.
    Rao, Mayuree
    Ali, Mohammed K.
    Riley, Leanne M.
    Robinson, Carolyn A.
    Ezzati, Majid
    [J]. LANCET, 2011, 378 (9785) : 31 - 40
  • [6] Recent developments in the discovery of FFA1 receptor agonists as novel oral treatment for type 2 diabetes mellitus
    Defossa, Elisabeth
    Wagner, Michael
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2014, 24 (14) : 2991 - 3000
  • [7] From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
    DeFronzo, Ralph A.
    [J]. DIABETES, 2009, 58 (04) : 773 - 795
  • [8] Fujiwara K., 2005, AM J PHYSIOL-ENDOC M, V280, P670
  • [9] Ligand efficiency: a useful metric for lead selection
    Hopkins, AL
    Groom, CR
    Alex, A
    [J]. DRUG DISCOVERY TODAY, 2004, 9 (10) : 430 - 431
  • [10] AMG 837: A potent, orally bioavailable GPR40 agonist
    Houze, Jonathan B.
    Zhu, Liusheng
    Sun, Ying
    Akerman, Michelle
    Qiu, Wei
    Zhang, Alex J.
    Sharma, Rajiv
    Schmitt, Michael
    Wang, Yingcai
    Liu, Jiwen
    Liu, Jingian
    Medina, Julio C.
    Reagan, Jeff D.
    Luo, Jian
    Tonn, George
    Zhang, Jane
    Lu, Jenny Ying-Lin
    Chen, Michael
    Lopez, Edwin
    Nguyen, Kathy
    Yang, Li
    Tang, Liang
    Tian, Hui
    Shuttleworth, Steven J.
    Lin, Daniel C. -H.
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (02) : 1267 - 1270